Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
暂无分享,去创建一个
Won-Young Lee | Hyemi Kwon | Jinmi Lee | S. Hong | Sun Joon Moon | Se Eun Park | Min-Jeong Kim | Eun-Jung Rhee | S. Moon
[1] E. Rhee. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? , 2022, Endocrinology and metabolism.
[2] D. Giugliano,et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs , 2021, Cardiovascular Diabetology.
[3] R. Loomba,et al. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk , 2021, Current Diabetes Reports.
[4] S. E. Park,et al. Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling. , 2020, Biochemical and biophysical research communications.
[5] Xinfeng Liu,et al. Calcification in Atherosclerotic Plaque Vulnerability: Friend or Foe? , 2020, Frontiers in Physiology.
[6] M. Gilbert,et al. An overview of GLP-1 agonists and recent cardiovascular outcomes trials , 2019, Postgraduate Medical Journal.
[7] Jiao Zhang,et al. Angiotensin II Receptor Type 1 Antagonists Modulate Vascular Smooth Muscle Cell Proliferation and Migration via AMPK/mTOR , 2019, Cardiology.
[8] S. Surani,et al. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence , 2019, World journal of diabetes.
[9] S. Allahverdian,et al. Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[10] J. Marrs,et al. Antihyperglycemic Medications and Cardiovascular Risk Reduction , 2017, European endocrinology.
[11] K. Miyauchi,et al. Coronary Artery Disease and Type 2 Diabetes Mellitus. , 2017, International heart journal.
[12] Qinghua Wang,et al. Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies , 2017, Front. Physiol..
[13] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[14] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[15] M. Bennett,et al. Vascular Smooth Muscle Cells in Atherosclerosis. , 2016, Circulation research.
[16] J. Essers,et al. The renin-angiotensin system and its involvement in vascular disease. , 2015, European journal of pharmacology.
[17] Wei Jiang,et al. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways , 2015, Cardiovascular Diabetology.
[18] A. Orekhov,et al. Mechanisms of medial arterial calcification in diabetes. , 2014, Current pharmaceutical design.
[19] A. Sposito,et al. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists , 2014, Cardiovascular Diabetology.
[20] C. St. Hilaire,et al. Medial vascular calcification revisited: review and perspectives. , 2014, European heart journal.
[21] T. Jin,et al. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro. , 2013, American journal of physiology. Endocrinology and metabolism.
[22] L. Havekes,et al. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. , 2013, Atherosclerosis.
[23] M. Festing,et al. Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1 , 2010, Thrombosis and Haemostasis.
[24] E. Tomás,et al. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis , 2010, Trends in Endocrinology & Metabolism.
[25] T. Engstrøm,et al. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart , 2008, Regulatory Peptides.
[26] J. Holst,et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. , 2006, American journal of physiology. Endocrinology and metabolism.
[27] A. Van der Laarse,et al. Vascular smooth muscle cells and calcification in atherosclerosis. , 2004, American heart journal.
[28] C. Shanahan,et al. Biology of Calcification in Vascular Cells: Intima versus Media , 2001, Herz.
[29] L. B. Knudsen,et al. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.
[30] R. Pederson,et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.
[31] M. Bennett,et al. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment , 2021 .
[32] H. Vaudry,et al. How does angiotensin AT 2 receptor activation help neuronal differentiation and improve neuronal pathological situations , 2012 .
[33] Lubo Zhang,et al. Angiotensin II receptors and drug discovery in cardiovascular disease. , 2011, Drug discovery today.
[34] B. L. Metcalfe. DEFINING THE ROLE OF THE ANGIOTENSIN II TYPE 2 RECEPTOR IN CARDIOVASCULAR DISEASE , 2004 .